Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: Patentlawmeister who wrote (12151)	9/7/2005 1:43:54 PM
From: CusterInvestor	Read Replies (2) \| Respond to of 37387

Patent, if I can to what you said, I have had 30K of CTE with an average of near $1 for over 2 years. Saw it go to $7 and back down to 1.65. Still holding because of the potential holy grail of an artificial coronary bypass graft (CABG). Hindsight said I should have sold at 7, but I still think its worth more. Sold 1K today on premise of a short pop and further retreat, only to see it keep going. Just like you said, afraid of losing profit.

To: Patentlawmeister who wrote (12151)	9/7/2005 2:10:54 PM
From: rrufff	Respond to of 37387

CTE - CardioTech Stock Up on FDA Device Approval Wednesday September 7, 1:53 pm ET CardioTech Shares Soar As FDA Clears Coating for Transfusion Devices That Prevents Rejection WILMINGTON, Mass. (AP) -- Shares of CardioTech International Inc. jumped sharply Wednesday after the medical device maker said the Food and Drug Administration approved its coated heart-lung bypass products, which are designed to prevent patients' immune systems from rejecting foreign objects. CardioTech shares rose 59 cents, or 34 percent, to $2.35 on the American Stock Exchange. A year ago the stock traded at a 52-week high of $3.38, but shares have since steadily declined, recently reaching a year-low of $1.69. Shares are down 20 percent so far this year. The company received FDA clearance to market its transfusion and blood reservoir devices with GBS Coating. GBS is made from heparin, a blood thinner, and hyaluronic acid, a natural protein found in the skin and joints, and is designed to be blood-compatible in order to cut down on the likelihood of a patient's immune system rejecting a foreign device. CardioTech said the potential market for coated heart-lung bypass products in the U.S. is estimated at $250 million annually. With a worldwide market projected at $500 million, the company hopes to get European approval for the coated devices in 2006, as a larger percent of EU customers demand coated products versus the U.S.